\-\ Texto\\:\\ \ \(0\)\
\-\ non\\-focal\\ neurologic\\ examination\\.\ \(1\)\
\-\ ct\\:\\ a\\ hyperdense\\ mass\\ infiltrating\\ and\\ widening\\ the\\ splenium\\ of\\ the\\ corpus\\ callosum\\.\\ a\\ poorly\\ defined\\ subtle\\ hypodense\\ lesion\\ at\\ the\\ level\\ of\\ the\\ right\\ basal\\ ganglia\\ that\\ causes\\ leftward\\ midline\\ shift\\ and\\ mass\\ effect\\ on\\ the\\ right\\ lateral\\ ventricle\\.\ \(0\)\
\-\ mri\\:\\ a\\ poorly\\ defined\\ t2\\ hyperintense\\ lesion\\ infiltrating\\ and\\ widening\\ the\\ splenium\\ of\\ the\\ corpus\\ callosum\\ with\\ an\\ additional\\ focus\\ at\\ the\\ level\\ of\\ the\\ right\\ basal\\ ganglia\\ that\\ causes\\ leftward\\ midline\\ shift\\.\\ vasogenic\\ edema\\ in\\ the\\ right\\ posterior\\ cerebral\\ hemisphere\\.\\ the\\ mass\\ has\\ mild\\,\\ irregular\\ enhancement\\.\ \(0\)\
\-\ glioblastoma\\ multiforme\\ with\\ gliomatosis\\ cerebri\ \(0\)\
\-\ \\â\\€\\¢\\ glioblasatoma\\ multiforme\\ \ \(0\)\
\-\ \\â\\€\\¢\\ gliomatosis\\ cerebri\ \(0\)\
\-\ \\â\\€\\¢\\ multiple\\ sclerosis\ \(0\)\
\-\ \\â\\€\\¢\\ lymphoma\ \(6\)\
\-\ \\â\\€\\¢\\ metastatic\\ disease\ \(13\)\
\-\ 56\\ y\\.o\\.\\ woman\\ with\\ vague\\ neurological\\ symptoms\\ such\\ as\\ headache\\ and\\ lethargy\\ that\\ were\\ increasing\\ over\\ a\\ few\\ weeks\\.\ \(1\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ gliomatosis\\:\\ 0\\.2668355187348019\ \(0\)\
\-\ leftward\\:\\ 0\\.2558515099417993\ \(0\)\
\-\ splenium\\:\\ 0\\.24515374091985484\ \(0\)\
\-\ cerebri\\:\\ 0\\.2275344995831967\ \(0\)\
\-\ the\\:\\ 0\\.2159266324477177\ \(0\)\
\-\ multiforme\\:\\ 0\\.20503469857854134\ \(0\)\
\-\ infiltrating\\:\\ 0\\.19302101050189036\ \(0\)\
\-\ callosum\\:\\ 0\\.18532441130951097\ \(0\)\
\-\ ganglia\\:\\ 0\\.1849209950796211\ \(0\)\
\-\ widening\\:\\ 0\\.18148805068730406\ \(0\)\
\-\ corpus\\:\\ 0\\.17937565427795246\ \(0\)\
\-\ poorly\\:\\ 0\\.17770906467404424\ \(0\)\
\-\ shift\\:\\ 0\\.17286015498679727\ \(0\)\
\-\ basal\\:\\ 0\\.1683606138189261\ \(0\)\
\-\ glioblasatoma\\:\\ 0\\.15732558013424738\ \(0\)\
\-\ causes\\:\\ 0\\.14867076780361269\ \(0\)\
\-\ midline\\:\\ 0\\.1479767465123761\ \(0\)\
\-\ defined\\:\\ 0\\.14036269628909723\ \(0\)\
\-\ right\\:\\ 0\\.13046363674279363\ \(0\)\
\-\ that\\:\\ 0\\.12807524916155383\ \(0\)\
\-\ level\\:\\ 0\\.11885030260287419\ \(0\)\
\-\ mass\\:\\ 0\\.11273169077351335\ \(0\)\
\-\ lethargy\\:\\ 0\\.10950993860055451\ \(0\)\
\-\ glioblastoma\\:\\ 0\\.09810356141799673\ \(0\)\
\-\ vasogenic\\:\\ 0\\.0967660039570861\ \(0\)\
\-\ vague\\:\\ 0\\.09625873658639539\ \(0\)\
\-\ hypodense\\:\\ 0\\.09552475997798685\ \(0\)\
\-\ lesion\\:\\ 0\\.09432784903961698\ \(0\)\
\-\ hemisphere\\:\\ 0\\.09206402382062998\ \(0\)\
\-\ 56\\:\\ 0\\.09186915341696052\ \(0\)\
\-\ hyperdense\\:\\ 0\\.09056343890584748\ \(0\)\
\-\ subtle\\:\\ 0\\.0848120935736629\ \(0\)\
\-\ few\\:\\ 0\\.08345150069450634\ \(0\)\
\-\ focus\\:\\ 0\\.08333297206828351\ \(0\)\
\-\ and\\:\\ 0\\.0813132695863512\ \(0\)\
\-\ neurological\\:\\ 0\\.08081004097783365\ \(0\)\
\-\ neurologic\\:\\ 0\\.07860952852242424\ \(0\)\
\-\ hyperintense\\:\\ 0\\.07825393144534683\ \(0\)\
\-\ increasing\\:\\ 0\\.0774796736169005\ \(0\)\
\-\ of\\:\\ 0\\.07700745099034456\ \(0\)\
\-\ additional\\:\\ 0\\.07626181384101707\ \(0\)\
\-\ irregular\\:\\ 0\\.07595106944781585\ \(0\)\
\-\ at\\:\\ 0\\.07431616506334227\ \(0\)\
\-\ ventricle\\:\\ 0\\.07241351424482738\ \(0\)\
\-\ sclerosis\\:\\ 0\\.07007150161248168\ \(0\)\
\-\ effect\\:\\ 0\\.06900988359404997\ \(0\)\
\-\ cerebral\\:\\ 0\\.06815620305378355\ \(0\)\
\-\ headache\\:\\ 0\\.06781661140451797\ \(0\)\
\-\ such\\:\\ 0\\.06328083511834734\ \(0\)\
\-\ examination\\:\\ 0\\.0629516360982065\ \(0\)\
\-\ weeks\\:\\ 0\\.058959018946621644\ \(0\)\
\-\ edema\\:\\ 0\\.05867395713036251\ \(0\)\
\-\ lymphoma\\:\\ 0\\.05858934937000419\ \(0\)\
\-\ with\\:\\ 0\\.05779009719297107\ \(0\)\
\-\ enhancement\\:\\ 0\\.05662385126266088\ \(0\)\
\-\ t2\\:\\ 0\\.056598766389540894\ \(0\)\
\-\ mild\\:\\ 0\\.05576689051228251\ \(0\)\
\-\ over\\:\\ 0\\.05470170775557782\ \(0\)\
\-\ metastatic\\:\\ 0\\.05395463706002733\ \(0\)\
\-\ symptoms\\:\\ 0\\.053826095988706586\ \(0\)\
\-\ woman\\:\\ 0\\.051234848449841566\ \(0\)\
\-\ posterior\\:\\ 0\\.05087138194655898\ \(0\)\
\-\ were\\:\\ 0\\.050710288273859004\ \(0\)\
\-\ mri\\:\\ 0\\.050497811082310703\ \(0\)\
\-\ lateral\\:\\ 0\\.04882213992024366\ \(0\)\
\-\ multiple\\:\\ 0\\.04811813003914811\ \(0\)\
\-\ has\\:\\ 0\\.04493555873845859\ \(0\)\
\-\ disease\\:\\ 0\\.04129499659728965\ \(0\)\
\-\ as\\:\\ 0\\.039521366640323685\ \(0\)\
\-\ an\\:\\ 0\\.037618876854337055\ \(0\)\
\-\ ct\\:\\ 0\\.0374528905178587\ \(0\)\
\-\ on\\:\\ 0\\.029711418046485125\ \(0\)\
\-\ in\\:\\ 0\\.024472902256823567\ \(0\)\
